Author

D. Memon

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Research Focus:differential expression· 2 Assay:proteomics· 2 Approach:statistical model· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

P. Beltrao· 3 shared A. Chow· 1 shared A. Dugourd· 1 shared A. Garcia-Sastre· 1 shared A. J. Minn· 1 shared A. J. Plodkowski· 1 shared A. J. Schoenfeld· 1 shared A. L. Richards· 1 shared

Activity by Year

2021-2021 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

P. Beltrao

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer

D. Memon, H. Rizvi, G. Fromm, J. Lihm, A. J. Schoenfeld, J. L. Sauter, J. Luo, A. Chow, U. K. Bhanot, C. McCarthy, D. Ye, C. M. Vanderbilt, C. Liu, M. Abu-Akeel, A. J. Plodkowski, , M. D. Hellmann

This study characterizes clinical and molecular features of acquired resistance to PD-(L)1 blockade in NSCLC, identifying persistent inflammation and dysfunctional IFN signaling as key features.

bioRxiv · Jul 21, 2021Cancer Biology

Pan-Cancer landscape of protein activities identifies drivers of signalling dysregulation and patient survival

A. Sousa, A. Dugourd, D. Memon, B. Petursson, E. Petsalaki, J. Saez-Rodriguez, P. Beltrao

The paper analyzes protein activity changes in cancer using genomics and proteomics data to identify drivers of signaling dysregulation and their impact on patient survival.

bioRxiv · Jun 9, 2021Cancer Biology

Evolution of enhanced innate immune evasion by the SARS-CoV-2 B.1.1.7 UK variant

L. G. Thorne, M. Bouhaddou, A.-K. Reuschl, L. Zuliani-Alvarez, B. J. Polacco, A. Pelin, J. Batra, M. V. X. Whelan, M. Ummadi, A. Roic, J. Turner, K. Obernier, H. Braberg, M. Soucheray, A. L. Richards, , N. J. Krogan

This study identifies that the B.1.1.7 SARS-CoV-2 variant enhances innate immune evasion through increased Orf9b and Orf6 expression and activity.

bioRxiv · Jun 6, 2021 · PreprintMicrobiology